X-linked agammaglobulinemia (XLA), or Bruton agammaglobulinemia, is an inherited immunodeficiency disease caused by mutations in the gene coding for Bruton tyrosine kinase (BTK). BTK is critical to the maturation of preB cells to differentiating mature B cells. No curative therapy exists for X-linked agammaglobulinemia (XLA), or Bruton agammaglobulinemia.
Treatment of X-linked agammaglobulinemia
Treatment for XLA is IVIG. Typical doses are 400-600 mg/kg/mo given every 3-4 weeks. Doses and intervals can be adjusted based on individual clinical responses. Therapy should begin at age 10-12 weeks. Maintenance of an IgG trough level of 500-800 mg/dL is recommended. Therapy should be started at age 10-12 weeks. Currently, no evidence supports that one particular brand or route of administration (IV vs SC) is better than the other.
Major Research on X-linked agammaglobulinemia in Sweden
The research being carried out throughout the country can be stated as Gene and cell therapy for X-linked agammaglobulinemia.
Disease Statistics of X-linked agammaglobulinemia
The disease statistics can be observed as 8,986,400 of the total population are prone to the disease.